

Table SI. Clinicopathological characteristics of study patients with AR and NALR before matching.

Variable	AR (n=21)	NALR (n=67)	P-value
Sex			
Male (%)	13 (61.9)	42 (62.7)	0.95
Age			
≥65 years (%)	10 (47.6)	34 (50.8)	0.80
Tumor location			
Rectum (%)	8 (38.1)	41 (61.2)	0.06
Pre-operative CEA			
≥5 ng/ml (%)	11 (52.4)	44 (65.7)	0.27
Pre-operative CA19-9			
≥37 ng/ml (%)	3 (14.3)	33 (49.3)	0.005
T stage			
T3-4 (%)	20 (95.2)	61 (91.0)	0.54
N stage			
N1-2 (%)	15 (71.4)	44 (65.7)	0.62
Tumor diameter			
≥50 mm (%)	11 (52.4)	34 (50.8)	0.89
Histological type			
Tub (%)	20 (95.2)	62 (92.5)	0.67
Lymphatic invasion			
Positive (%)	10 (47.6)	25 (37.3)	0.40
Venous invasion			
Positive (%)	16 (76.2)	59 (88.1)	0.18
Pathological stage			
I-II	6	22	0.68
III	11	28	
IV	4	17	

All patients with missing data were excluded. AR, anastomotic recurrence; NALR, non-anastomotic recurrence; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; Tub, tubular adenocarcinoma.

Table SII. Information on recurrent tumors for patients with NALR.

No.	<i>KRAS G13D</i>	<i>RAS</i> status	Age, years	Sex	Tumor location
1	+	G13D	72	F	Sigmoid
2	-	G12D	59	M	Sigmoid
3	-	G12D	68	M	Sigmoid
4	-	G12D	58	M	Rectum
5	-	G12V	71	F	Sigmoid
6	-	G12V	62	M	Sigmoid
7	-	G12A	66	F	Sigmoid
8	-	WT	48	M	Rectum
9	-	WT	52	F	Sigmoid
10	-	WT	64	M	Rectum
11	-	WT	66	F	Sigmoid
12	-	Not tested	66	F	Rectum
13	-	Not tested	62	M	Sigmoid
14	-	Not tested	70	M	Rectum
15	-	Not tested	71	M	Sigmoid
16	-	Not tested	56	M	Rectum

17	-	Not tested	76	M	Sigmoid
18	-	Not tested	47	F	Rectum
19	-	Not tested	61	F	Rectum
20	-	Not tested	64	M	Sigmoid
21	-	Not tested	83	M	Transverse

NALR, non-anastomotic local recurrence; G13D, *KRAS G13D* mutant; G12D, *KRAS G12D* mutant; WT, *KRAS* wild-type; F, female; M, male.